{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:19:19Z","timestamp":1794406759406,"version":"4.9.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gynecologic Oncology Group Statistical and Data Center","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}]},{"name":"NRG Oncology","award":["1 U10 CA180822"],"award-info":[{"award-number":["1 U10 CA180822"]}]},{"name":"NRG Operations","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ygyno.2018.10.001","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T13:38:59Z","timestamp":1539005939000},"page":"422-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology\/gynecologic oncology group study"],"prefix":"10.1016","volume":"151","author":[{"given":"Bradley J.","family":"Monk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Kauderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Moxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Bonebrake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer B.","family":"Dewdney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.10.001_bb0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.001_bb0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.001_bb0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80\u202fmg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.001_bb0020","doi-asserted-by":"crossref","first-page":"7s","DOI":"10.1200\/jco.2010.28.15_suppl.5010","article-title":"A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group (GOG) study","volume":"28","author":"Coleman","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.001_bb0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2008.07.049","article-title":"A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group study","volume":"111","author":"Sabbatini","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.001_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40661-017-0050-0","article-title":"Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?","volume":"4","author":"Herzog","year":"2017","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.ygyno.2018.10.001_bb0035","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bcp.2014.12.008","article-title":"Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)","volume":"93","author":"Hasinoff","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"31","key":"10.1016\/j.ygyno.2018.10.001_bb0040","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1200\/JCO.2012.44.5585","article-title":"Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma","volume":"20","author":"O'Day","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.10.001_bb0045","first-page":"574","article-title":"Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70","volume":"7","author":"Gehrmann","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ygyno.2018.10.001_bb0050","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1158\/1078-0432.CCR-06-0964","article-title":"Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors","volume":"13","author":"Berkenblit","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.10.001_bb0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.10.001_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal 2-stage trial design for phase II trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"issue":"20","key":"10.1016\/j.ygyno.2018.10.001_bb0070","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2018.10.001_bb0075","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818312812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818312812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:39:09Z","timestamp":1758771549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818312812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0090825818312812"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.10.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology\/gynecologic oncology group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}